Fol­low­ing US, Chi­na hos­pi­tal ef­forts, Gilead plots its own PhI­II tri­als for close­ly watched Covid-19 drug

Gilead is launch­ing its own Phase III tri­als of remde­sivir, the re­pur­posed an­tivi­ral that a WHO of­fi­cial called the “one drug right now we think may have re­al ef­fi­ca­cy” against Covid-19 as the nov­el coro­n­avirus orig­i­nat­ing from Wuhan, Chi­na rav­ages the world.

An­nounced just a day af­ter the NIH and the Uni­ver­si­ty of Ne­bras­ka Med­ical Cen­ter reg­is­tered their US-based tri­al on­line, Gilead’s pro­gram will com­prise two stud­ies en­rolling around 1,000 pa­tients be­gin­ning in March. They will re­cruit pri­mar­i­ly in Asian coun­tries but will al­so in­clude pa­tients from oth­er lo­ca­tions with “high num­bers of di­ag­nosed cas­es,” the com­pa­ny said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.